Akshat Jain: US FDA approves Marstacimab for Hemophilia A or B without inhibitors in adults and adolescents

Akshat Jain shared a post on X:

“U.S. FDA approves Pfizer Marstacimab for the treatment of adults and adolescents with hemophilia A or B without inhibitors!

• HYMPAVZI
• Data from BASIS trial, where ABR went from 7 O to 5.1 at the end of trial to 2.8 at extension in prophylaxis group (EHA Hematology).
• Only weekly dosing.
  
• Prefilled device!
  
• Hemophilia B with inhibitors patients will have to wait.
  
• Cost comparison with other non factor therapy Roche and Genentech will be interesting.
• Head to Head comparison to see rate of ABR and AJBRs in min factor therapy needed.”

Read further.

More posts featuring Akshat Jain on oncodaily.com.

Akshat Jain, M.D., M.P.H., is a Medical Director at Loma Linda University Children’s Health, overseeing the Pediatric and Young Adult Hemostasis/Thrombosis and Sickle Cell Disease Program.

He serves as a Clinical Faculty member in Pediatric Hematology-Oncology at Loma Linda University Medical Center and is on the Clinical Science Faculty Advisory Council. Additionally, he is an Assistant Professor at the Loma Linda University School of Public Health and a Review Board Member for Hemostasis with the American Academy of Pediatrics.